Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

Blood cancers such as leukaemia and lymphoma
Inherited genetic disorders including thalassemia and sickle cell disease
Neurological conditions such as cerebral palsy and brain injury
Immune deficiencies and metabolic disorders
Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

Cerebral Palsy
Thalassemia
Leukaemia
HSV Encephalitis
Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

Families gain access to 1,000,000+ stored cord blood units across the network
Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

Order now Find out more

FamiCord Group releases

Patients

7800+

Expand table
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
8301	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2014	Standard Therapy	Germany	55
8302	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2014	Standard Therapy	Germany	57
8303	Apheresis	Allogeneic	Myeloproliferative Neoplasms	Hematology	2014	Standard Therapy	Germany	56
8304	Apheresis	Allogeneic	Myeloproliferative Syndrome	Hematology	2014	Standard Therapy	Germany	60
8305	Apheresis	Autologous	Neuroblastoma	Hematology	2014	Standard Therapy	Germany	7
8306	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2014	Standard Therapy	Germany	60
8307	Apheresis	Allogeneic	Non-Hodgkin Lymphoma	Hematology	2014	Standard Therapy	Germany	43
8308	Apheresis	Autologous	Post-Transplant Lymphoproliferative Disorder	Hematology	2014	Standard Therapy	Germany	60
8309	Apheresis	Autologous	Primary Central Nervous System Lymphoma	Hematology	2014	Standard Therapy	Germany	69
8310	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2014	Standard Therapy	Germany	64
8311	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2014	Standard Therapy	Germany	42
8312	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2014	Standard Therapy	Germany	51
8313	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2014	Standard Therapy	Germany	56
8314	Apheresis	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2014	Standard Therapy	Germany	75
8315	Apheresis	Autologous	Secondary Lymphoma	Hematology	2014	Standard Therapy	Germany	59
8316	Apheresis	Autologous	T-Cell Lymphoblastic Lymphoma	Hematology	2014	Standard Therapy	Germany	54
8317	Apheresis	Autologous	T-Cell Non-Hodgkin Lymphoma	Hematology	2014	Standard Therapy	Germany	46
8318	Apheresis	Autologous	T-Cell Non-Hodgkin Lymphoma	Hematology	2014	Standard Therapy	Germany	48
8319	Apheresis	Autologous	T-Cell Non-Hodgkin Lymphoma	Hematology	2014	Standard Therapy	Germany	43
8320	Apheresis	Allogeneic	T-Cell Non-Hodgkin Lymphoma Relapse	Hematology	2014	Standard Therapy	Germany	56
8321	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2013	Experimental Therapy	Poland	18,9
8322	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2013	Experimental Therapy	Poland	2,11
8323	Cord Tissue	Allogeneic – Unrelated	Acute Graft Versus Host Disease	Hematology	2013	Experimental Therapy	Poland	3,5
8324	Cord Tissue	Allogeneic – Unrelated	Acute Myeloid Leukemia	Hematology	2013	Experimental Therapy	Poland	3,5
8325	Cord Tissue	Allogeneic – Unrelated	Chronic Graft Versus Host Disease	Hematology	2013	Experimental Therapy	Poland	18,8
8326	Cord Tissue	Allogeneic – Unrelated	Chronic Graft Versus Host Disease	Hematology	2013	Experimental Therapy	Poland	17,5
8327	Cord Blood	Allogeneic – Related	Acute Lymphoblastic Leukemia	Hematology	2013	Standard Therapy	Germany	8
8328	Cord Blood	Allogeneic – Related	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Poland	3
8329	Cord Blood	Allogeneic – Related	Aplastic Anemia	Hematology	2013	Standard Therapy	Poland	3
8330	Cord Blood	Allogeneic – Related	Leukemia	Hematology	2013	Standard Therapy	Turkey	7
8331	Cord Blood	Allogeneic – Related	Thalassemia	Hematology	2013	Standard Therapy	UK	5
8332	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2013	Standard Therapy	Turkey	7,12
8333	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2013	Standard Therapy	Turkey	3
8334	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2013	Standard Therapy	Turkey	?
8335	Cord Blood	Allogeneic – Related	Wiskott-Aldrich Syndrome	Hematology	2013	Standard Therapy	Germany	3
8336	Cord Blood	Allogeneic – Related	X-Linked Lymphoproliferative Syndrome	Hematology	2013	Standard Therapy	Poland	10 months
8337	Bone Marrow Family	Allogeneic	Follicular Lymphoma + Non-Hodgkin-Hodgkin	Hematology	2013	Standard Therapy	Germany	38
8338	Bone Marrow Family	Allogeneic	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	58
8339	Bone Marrow Family	Allogeneic	Myelodysplastic Syndrome	Hematology	2013	Standard Therapy	Germany	73
8340	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2013	Standard Therapy	Germany	71
8341	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2013	Standard Therapy	Germany	44
8342	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	17
8343	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	55
8344	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	51
8345	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	21
8346	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	18
8347	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	59
8348	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2013	Standard Therapy	Germany	55
8349	Apheresis	Allogeneic	Acute Myeloid Leukemia – Relapse	Hematology	2013	Standard Therapy	Germany	62
8350	Apheresis	Autologous	Angioimmunoblastic Lymphadenopathy With Dysproteinemia – Relapse	Hematology	2013	Standard Therapy	Germany	51
8351	Apheresis	Autologous	Angioimmunoblastic Lymphadenopathy With Dysproteinemia – Relapse	Hematology	2013	Standard Therapy	Germany	54
8352	Apheresis	Allogeneic	B-Cell Acute Lymphoblastic Leukemia	Hematology	2013	Standard Therapy	Germany	55
8353	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2013	Standard Therapy	Germany	62
8354	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma – Relapse	Hematology	2013	Standard Therapy	Germany	52
8355	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma – Relapse	Hematology	2013	Standard Therapy	Germany	32
8356	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma – Relapse	Hematology	2013	Standard Therapy	Germany	51
8357	Apheresis	Autologous	Burkitt Lymphoma	Hematology	2013	Standard Therapy	Germany	49
8358	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2013	Standard Therapy	Germany	48
8359	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2013	Standard Therapy	Germany	48
8360	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2013	Standard Therapy	Germany	64
8361	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2013	Standard Therapy	Germany	61
8362	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2013	Standard Therapy	Germany	54
8363	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2013	Standard Therapy	Germany	62
8364	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2013	Standard Therapy	Germany	54
8365	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2013	Standard Therapy	Germany	39
8366	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2013	Standard Therapy	Germany	43
8367	Apheresis	Allogeneic	Hypoplastic Myelodysplastic Syndrome	Hematology	2013	Standard Therapy	Germany	32
8368	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2013	Standard Therapy	Germany	47
8369	Apheresis	Autologous	Morbus Hodgkin-Relapse	Hematology	2013	Standard Therapy	Germany	50
8370	Apheresis	Autologous	Morbus Hodgkin-Relapse	Hematology	2013	Standard Therapy	Germany	62
8371	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	70
8372	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	52
8373	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	48
8374	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	65
8375	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	62
8376	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	73
8377	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	55
8378	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	53
8379	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	56
8380	Apheresis	Allogeneic	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	61
8381	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	54
8382	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	60
8383	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	64
8384	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	66
8385	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	59
8386	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	65
8387	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	59
8388	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	65
8389	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	45
8390	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	50
8391	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	78
8392	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	46
8393	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	53
8394	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	65
8395	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	61
8396	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	40
8397	Apheresis	Autologous	Multiple Myeloma	Hematology	2013	Standard Therapy	Germany	58
8398	Apheresis	Allogeneic	Mycosis Fungoides	Hematology	2013	Standard Therapy	Germany	62
8399	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2013	Standard Therapy	Germany	62
8400	Apheresis	Autologous	Neuroblastoma	Hematology	2013	Standard Therapy	Germany	3

Page 84 of 89 1 82 83 84 85 86 89

Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

100% infusion success rate

For samples released for transplant.

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

Expand table
Sample release date	Medical condition	Recipient relationship	Age of the recipient	Unit volume	Medical center	Country
2005.11	Thalassemia	Allogeneic (Sibling)	4 Years	144ml	Mount Vernon Hospital	Singapore
2005.11	Leukaemia	Allogeneic (Sibling)	Restricted	Restricted	Stem Cells and Immunology Department, Birmingham	UK
2007.02	Thalassemia	Allogeneic (Sibling)	7 Years	76ml	Kinderlink der Tu Munchen	Germany
2009.08	Cerebral Palsy	Autologous (Self)	3 Years	51ml	Duke University, North Carolina	USA
2010.01	Cerebral Palsy	Autologous (Self)	3 Years	81ml	Duke University, North Carolina	USA
2013.10	Thalassemia	Allogeneic (Sibling)	5 Years	58ml	Catherine Lewis Centre, Hammersmith	UK
2014.01	Leukaemia	Allogeneic (Sibling)	4 Years	71ml	Medizinische Hochschule, Hanover	Germany
2014.05	Cerebral Palsy	Autologous (Self)	1 year	68ml	Duke University, North Carolina	USA
2014.06	HSV Encephalitis & NMDA Receptor Antibody Virus	Autologous (Self)	2 Years	57ml	Duke University, North Carolina	USA
2014.08	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	3 Months	39ml	Duke University, North Carolina	USA
2015.02	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	6 Months	53ml	Duke University, North Carolina	USA
2015.03	Severe Combined Immune Deficiency	Autologous (Self)	3 Months	74ml	Duke University, North Carolina	USA
2015.03	Sickle Cell Disease	Allogeneic (Sibling)	2 .5 Years	57ml	BLK Hospital, New Delhi	India
2015.11	Thalassemia	Allogeneic (Sibling)	12 Years	87ml	Children’s Hospital of Pittsburgh of UPMC	USA
2016.03	Cerebral Palsy	Allogeneic (Sibling)	6 Years	101ml	Duke University, North Carolina	USA
2017.04	Lymphoblastic Leukaemia (^1)	N/A (Identical twin girls)	Restricted	125ml	Bambin Gesu Childrens’ Hospital, Rome	Italy
2017.06	Cerebral Palsy	Autologous (Self)	7 Years	82ml	Duke University, North Carolina	USA
2017.06	Cerebral Palsy	Autologous (Self)	3.4 Years	132ml	Duke University, North Carolina	USA
2018.03	Autism	Autologous (Self)	5.4 Years	73ml	Duke University, North Carolina	USA
2018.03	Cerebral Palsy	Autologous (Self)	3.4 years	132ml	Duke University, North Carolina	USA
2019.06	Cerebral Palsy	Allogeneic (Sibling)	3 Years	104ml	Duke University, North Carolina	USA
2022.02	Cerebral Palsy	Allogeneic (Sibling)	11 Years	185ml	Duke University, North Carolina	USA
2023.08	Cerebral Palsy	Allogeneic (Sibling)	3 Years	46ml	Duke University, North Carolina	USA
2024.01	Thalassaemia	Allogeneic (Sibling)	8 Years	45ml	Cincinnati Children’s Hospital Medical Center	USA